Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults
Authors: Alan C. Moses, Yehuda Handelsman, Daniel Einhorn
Journal: Annals of Internal Medicine (2012)

Letters7 February 2012Effectiveness of Primary Care–Relevant Treatments for Obesity in AdultsAlan C. Moses, MD, Yehuda Handelsman, MD, and Daniel Einhorn, MDAlan C. Moses, MDFrom Novo Nordisk Inc, Princeton, NJ 08540; Metabolic Institute of America, Tarzana, CA 91356; and Scripps Whittier Diabetes Institute, University of California, San Diego, San Diego, CA 92123.Search for more papers by this author, Yehuda Handelsman, MDFrom Novo Nordisk Inc, Princeton, NJ 08540; Metabolic Institute of America, Tarzana, CA 91356; and Scripps Whittier Diabetes Institute, University of California, San Diego, San Diego, CA 92123.Search for more papers by this author, and Daniel Einhorn, MDFrom Novo Nordisk Inc, Princeton, NJ 08540; Metabolic Institute of America, Tarzana, CA 91356; and Scripps Whittier Diabetes Institute, University of California, San Diego, San Diego, CA 92123.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-3-201202070-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The review by LeBlanc and colleagues (1) for the USPSTF emphasizes that behavioral interventions producing weight loss can reduce the incidence of type 2 diabetes mellitus by up to 50%. We support the screening recommendations for obesity, but believe that there are discrepancies between these guidelines and the 2008 USPSTF recommendations for this disorder (2). Namely, the USPSTF recommends screening for obesity, despite no evidence of long-term health gains from randomized, prospective screening trials (1), but ignores the clear epidemiologic and etiologic relationship between obesity and type 2 diabetes mellitus by advocating screening in asymptomatic individuals only ...References1. LeBlanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434-47. [PMID: 21969342] LinkGoogle Scholar2. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148:846-54. [PMID: 18519930] LinkGoogle Scholar3. Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, et al; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2 1-53. [PMID: 21474420] CrossrefMedlineGoogle Scholar4. Sheehy AM, Flood GE, Tuan WJ, Liou JI, Coursin DB, Smith MA. Analysis of guidelines for screening diabetes mellitus in an ambulatory population. Mayo Clin Proc. 2010;85:27-35. [PMID: 20042558] CrossrefMedlineGoogle Scholar5. United Nations Resolution 61/225: World Diabetes Day. Accessed at www.worlddiabetesfoundation.org/media(3892,1033)/UNR_media_kit_0407.pdf on 19 October 2011. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Novo Nordisk Inc, Princeton, NJ 08540; Metabolic Institute of America, Tarzana, CA 91356; and Scripps Whittier Diabetes Institute, University of California, San Diego, San Diego, CA 92123.Acknowledgment: The authors thank John Smith, PhD, of Novo Nordisk, for assistance in drafting this letter.Disclosures: Dr. Moses: Payment for writing or reviewing the manuscript: Novo Nordisk; Employment: Novo Nordisk; Payment for manuscript preparation: Novo Nordisk; Stock/stock options: Novo Nordisk. Dr. Handelsman: Consultancy: Abbott, Amylin, Daiichi Sankyo, Gilead, GlaxoSmithKline, Genentech, Merck & Co., Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Tolerx, Xoma; Grants/grants pending: Boehringer Ingleheim, ConjuChem, Daiichi Sankyo, GlaxoSmithKline, Novo Nordisk, Sanofi, Takeda Pharmaceuticals, Xoma, Tolerx; Payment for lectures including service on speakers' bureaus: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Merck & Co., Novo Nordisk. Dr. Handelsman is also the President of the American Association of Clinical Endocrinologists. Dr. Einhorn: Consultancy: Amylin, Novo Nordisk; Grants/grants pending: Eli Lilly & Co., Sanofi, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim; Payment for lectures including service on speakers' bureaus: CME only; Stock/stock options: MannKind, Halozyme, Freedom-Meditech. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoScreening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation StatementEffectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force Erin S. LeBlanc , Elizabeth O'Connor , Evelyn P. Whitlock , Carrie D. Patnode , and Tanya Kapka Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults Erin S. LeBlanc and Elizabeth O'Connor Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults Lewis H. Kuller Metrics Cited byPredictors of engagement in postpartum weight self-management behaviours in the first 12 weeks after birthDiabetes Prevention 7 February 2012Volume 156, Issue 3Page: 248-249KeywordsBlood pressureEpidemiologyMedical risk factorsObesityOverweightScreening guidelinesSystolic pressureType 2 diabetesWeight loss ePublished: 7 February 2012 Issue Published: 7 February 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...